K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification

Etiquetas de revisión

Datos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.

Cómo se estudió

Diseño

Ensayo controlado aleatorizado (clasificado por nuestro filtro de IA)

Estudiado en

Personas

Resultado principal

Marcadores de salud y funcionamiento

Quién lo pagó

Financiación

Financiación no declarada

Publicación

Publicado

2017-01-01 · Am J Kidney Dis · vol. 42 · número 1 · págs. 33–42

Editorial

Karger Publishers

Citado

29,690 citas · más que el 100% de estudios similares · 1,380.9× el promedio de su campo

Impacto

Entre el 10 % más citado de su campo

Referencias

76 trabajos

Acceso

Acceso abierto (revista) · CC-BY-NC-ND

Áreas de investigación

Magnesium in Health and Disease · Parathyroid Disorders and Treatments · Potassium and Related Disorders

Palabras clave

Medicine, Internal medicine, Triglyceride, Placebo, Insulin resistance, Lipid profile, Endocrinology, Metabolic syndrome, Cholesterol, Diabetes mellitus, Insulin, Kidney disease, Blood lipids, Gastroenterology, Obesity

MeSH

humans, kidney diseases, cardiovascular diseases, chronic disease, age factors, adult, child, united states

6 autores

• Ömer Toprak🇹🇷Balıkesir University
• Hüseyin Kurt🇹🇷Balıkesir University
• Yasin Sarı🇹🇷Balıkesir University
• Cihat Şarkış🇹🇷Balıkesir University
• Halil Us🇹🇷Balıkesir University
• Ali Kırık🇹🇷Balıkesir University

Texto inicial

El texto original del estudio, en el idioma en que se publicó.

Este estudio se publicó sin resumen, como suele pasar con las cartas de investigación y los reportes breves. Así empieza; el texto completo se puede leer gratis.

BACKGROUND/AIMS: Magnesium is an essential mineral for many metabolic functions. There is very little information on the effect of magnesium supplementation on metabolic profiles of chronic kidney disease (CKD) patients. The aim of this study was to assess the influence of magnesium supplementation on metabolic profiles of pre-diabetic, obese and mild-to-moderate CKD patients with hypomagnesemia. METHODS: A total of 128 hypomagnesemic, pre-diabetic and obese patients with an estimated glomerular filtration rate between 90 and 30 ml/min/1.73m2 were enrolled in a randomised, double-blind, placebo-controlled trial. Patients in the magnesium group received 365 mg of oral magnesium (n = 57) once daily for 3 months, while patients in the control group received a placebo (n = 61), also once daily for 3 months. Hypomagnesemia is defined by a serum magnesium level <1.8 mg/dl in males and <1.9 mg/dl in females; obesity is defined as a body mass index ≥30 kg/m2; and pre-diabetes is defined as fasting plasma glucose ≥100 but <126 mg/dl. The primary end point of the study was the change in insulin resistance measured by the homeostastic model assessment for insulin resistance (HOMA-IR). RESULTS: At the end of follow-up, insulin resistance (-24.5 vs. -8.2%, P = 0.007), HOMA-IR index (-31.9 vs. -3.3%, P < 0.001), hemoglobin A1c (-6.6 vs. -0.16%, P < 0.001), insulin (-29.6 vs. -2.66%, P < 0.001), waist circumference (-4.8 vs. 0.55%, P < 0.001) and uric acid (-0.8 vs. 2.2%, P = 0.004) were significantly decreased in terms of mean changes; albumin (0.91 vs. -2.91%, P = 0.007) and magnesium (0.21 ± 0.18 vs. -0.04 ± 0.05 mg/dl, P < 0.001) were significantly increased in those taking magnesium compared with a placebo. The decrease in metabolic syndrome (-10.5 vs. -4.9%, P = 0.183), obesity (-15.7 vs. -8.2%, P = 0.131), pre-diabetes (-17.5 vs. -9.8%, P = 0.140), and systolic (-5.0 ± 14.8 vs. 0.22 ± 14.9 mm Hg, P = 0.053) and diastolic (-3.07 ± 9.7 vs. 0.07 ± 9.6 mm Hg, P = 0.071) blood pressure did not achieve to a significant level after study. CONCLUSION: Our data support the argument that magnesium supplementation improves the metabolic status in hypomagnesemic CKD patients with pre-diabetes and obesity.

Texto vía OpenAlex. Los derechos de autor siguen siendo de los autores o la editorial.

Confianza de la comunidad

Cargando…

¿Cuánto confías en los hallazgos de este estudio?

Comentarios

¿Algo está mal aquí?

Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.